Science and Technology Grants

The PWSA supports innovative research studies to advance research in preservation of function (physical ability), quality of life, symptom management, resilience, relief from neurocognitive deficits, and support for psychosocial issues related to cancer diagnosis, treatment, and survivorship. Studies must address one or more of these critical issues in at least one of the FY24 PRCRP Topic Areas. The overall intention of the PWSA is to fill gaps in the understanding of survivorship, including investigations into the psychological health and well-being of those affected by cancer (e.g., patients, family members). This may include investigations into studies that improve mental health and/or cancer-related outcomes in defined populations. Studies also may assess the relationship(s) between behavioral and social functioning in relation to cancer initiation, progression, detection, treatment, and rehabilitation. Applications may propose studies that examine preservation of function, quality-of-life, well-being, decision-making, and/or cognitive function, development and testing of educational interventions, and symptom management (e.g., toxicity of treatment, palliative/supportive care, psychological distress and anxiety) throughout treatment and beyond. Applications may target development of evidence-based practices, behavioral health science and patient well-being interventions and surveillance, and identification of psychosocial patient outcomes. Basic laboratory studies are not appropriate for the PWSA and may be withdrawn. The critical components of this award mechanism are: Impact: The PWSA is intended to support research that demonstrates the potential to have a major impact on patient well-being, outcomes, and health, including diagnosis, treatment, and after treatment. The proposed study must demonstrate how the research will transform outcomes related to at least one of the FY24 PRCRP Topic Areas. Research should challenge paradigms with respect to impact on patient care and outcomes. Proposed projects may include translational or clinical research, including pilot clinical trials. Impactful research will accelerate the movement of promising ideas into clinical applications and advance quality of life and survivorship. Study Design: Applications should clearly articulate the chosen design of the study. Studies entailing retrospective or prospective recruitment should define the type of architecture of the study (e.g., interventional, descriptive, correlational, field experimental, meta-analyses). Study populations should be clearly defined. The rationale should support the chosen study design with statistical evaluation to back the design. Questionnaires should be described in sufficient detail to justify interpretation of potential results. Studies utilizing animal models are not supported by this funding opportunity and may be withdrawn. Preliminary Data: The PWSA will require preliminary data for all studies that propose the active (prospective) recruitment of human subjects for pilot clinical trials. Studies not proposing active recruitment of human subjects are not required to present preliminary data but should be supported by sound reasoning and relevant literature. Patient Advocate Participation: Applications to the PWSA funding opportunity are required to include patient advocates. The research team must include at least one cancer patient advocate who will be integral throughout the planning and implementation of the research project. The patient advocate should be active in a cancer advocacy organization, have a high level of knowledge of current cancer issues, and be a representative from the FY24 PRCRP Topic Area(s) that is being studied. The patient advocate will be a person living with cancer; a person previously diagnosed with/treated for cancer but who now has no evidence of disease; or a family member or caretaker of someone with cancer. The patient advocate should be involved in the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. The role of the patient advocate should be focused on providing objective input on the research and its potential impact for individuals with or at risk for cancer.

The FY24 PCRP Exploration Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 PCRP Overarching Challenges. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Results of studies conducted through this award may provide the scientific premise upon which a new hypothesis can be based or initial proof of principle of an innovative hypothesis, laying the groundwork for future avenues of scientific investigation. Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, logical reasoning and a sound scientific rationale for the proposed work must be described. Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Submission Type, for more information. New for FY24: Clinical research is allowed. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities. Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. The funding instrument for awards made under the program announcement will be grants (31 USC 6304). The anticipated direct costs budgeted for the entire period of performance for an FY24 Exploration Hypothesis Development Award should not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $3.60M to fund approximately 15 Exploration Hypothesis Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030. Research Involving Animals: All research funded by the FY24 PCRP Exploration-Hypothesis Development Award involving new and ongoing research with animals must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO; previously the Human Research Protection Office), Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions for additional information.

This grant opportunity, offered by Sanofi, aims to address gaps and provide educational resources related to the diagnosis and treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). CIDP is a heterogeneous, immune-mediated neuropathy characterized by demyelination of motor and sensory nerves, leading to various clinical challenges. Sanofi seeks proposals for educational programs, particularly those that can effectively recap information from the 2024 Peripheral Nerve Society Annual Meeting and offer independent medical education (IME) activities. Programs should focus on key evidence-based data and offer recommendations to healthcare providers dealing with CIDP, particularly in areas such as treatment options, clinical challenges, and the role of complement therapeutics in CIDP care.

This grant provides funding for interdisciplinary research at U.S. higher education institutions and qualified non-profit organizations to advance the mathematical understanding of artificial intelligence and its applications.

This grant provides funding for researchers and conservation organizations in the U.S. to conduct studies that link scientific research on biodiversity with practical conservation efforts to protect ecosystems and species.

The DoD Peer Reviewed Cancer, Impact Award is a grant aimed at funding advanced research projects that can quickly translate promising findings into clinical applications, with the goal of making a significant, near-term impact on critical cancer issues and improving patient outcomes.

The PRCRP is seeking to advance cancer research through development of early-career investigators. Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PIs research and career development. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated. This award supports impactful research projects with an emphasis on discovery. The CDA-SO supports an independent, highly accomplished early-career investigator (referred to as a Scholar) to conduct impactful research under the guidance of an experienced cancer researcher (i.e., Career Guide). Scholars are required to participate in the unique, interactive Virtual Cancer Center (VCC) focused on fostering the next generation of cancer researchers. The overarching goal of the VCC is to develop successful, highly productive Scholars in a collaborative research and career developmental environment. The VCC will give Scholars opportunities to operate in a collegial, highly dynamic, and cutting edge research organization to lead cancer research to a new frontier. It is the intention that, through the VCC, collaborations will foster new growth to ensure the research advancements across different cancers. The VCC directorship is awarded through a separate mechanism, the Virtual Cancer Center Directors Award (VCCDA). The VCCDA calls for two established investigators (Director and Deputy Director) to provide intensive mentoring, national networking, collaborations, and a peer group for Scholars. In addition to their Career Guide, Scholars are required to interact with the VCC Director, Deputy Director, and fellow Scholars to include required attendance at in-person meeting with VCC Members annually. The intention of the Scholar Option is to support highly accomplished investigators toward the goal of leadership in cancer. The critical components of the Career Development Award: Principal Investigator: The PI must be an early-career researcher or physician-scientist within 7 years after completion of their terminal degree by the time of the application deadline (excluding time spent in residency, clinical training, or on family medical leave). Time spent as a postdoctoral fellow is not excluded. Postdoctoral fellows are not eligible for this award mechanism. The PIs record of accomplishments and the proposed research will be evaluated regarding their potential for contributing to at least one of the FY24 PRCRP Topic Areas. The Scholar must be in a tenure-track position or equivalent position. The Scholar must demonstrate significant accomplishments, including first-author publications, extramural funding (beyond nominal), and show excellence in cancer research as supported by letters of recommendation. The Scholar must have independent laboratory space separate from the Career Guides laboratory or other mentors laboratory. For more information on the eligibility criteria for the Virtual Cancer Center Scholar Option, refer to Section II.C.1. Career Guide: The Scholar must designate a Career Guide. The Career Guide must be an experienced cancer researcher, as demonstrated by a strong record of funding and publications. In addition, the Career Guide must demonstrate a commitment to advancing the PIs career in cancer research and be committed to fully participating in the VCC and potentially serving on the VCCs Advisory Board as requested by VCC Leadership. Career Development Plan: A career development plan is required and should be prepared with appropriate guidance from the Career Guide. The career development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, further independence, and expertise to advance their career at the forefront of cancer research in at least one of the FY24 PRCRP Topic Areas. Milestones: The Scholar must show career milestones and pathways toward achieving the milestones. The Scholar should demonstrate clear commitment to at least one of the FY24 PRCRP Topic Areas through a career development plan designed to enhance further networking and collaboration. Impact: The applicant must articulate the potential impact the proposed work will have on cancer research and/or patient care. Impactful research will accelerate the movement of promising ideas in cancer research into clinical applications.

The Water Resources Preservation Grant Program, funded by the Upper Guadalupe River Authority (UGRA), provides cost-share funding to support the design and construction of stormwater management practices. These practices, referred to as Best Management Practices (BMPs), include Low Impact Development (LID), nature-based solutions, and Green Stormwater Infrastructure (GSI). The goal is to reduce, infiltrate, filter, and delay stormwater runoff, thus protecting the health of waterways in Kerr County. Eligible projects can apply for rebates that cover a portion of the costs associated with these practices, with the aim of reducing pollutants like Total Suspended Solids (TSS) and Bacteria by significant percentages. The program supports new constructions or retrofits, emphasizes distributed and centralized treatment methods, and requires adherence to specific design guidelines.

This grant from Sanofi's Rare Blood Disorders Medical Affairs department focuses on medical education programs addressing Immune Thrombocytopenia (ITP). The grant aims to support independent medical education (IME) activities that recap highlights from EHA 2024 and ISTH 2024 conferences on ITP, emphasizing enduring programs, accredited or non-accredited IME activities, and digital or omnichannel formats. Proposals should address existing healthcare gaps in the treatment and management of ITP, improving clinician knowledge and patient outcomes. The maximum grant request is $150,000, with a focus on comprehensive interventions that address knowledge and performance gaps in ITP treatment. Proposals should cover target audience generation, learning objectives, educational methods, faculty recruitment, program evaluation, and budget planning.

This program provides matching funds to Texas public universities to attract distinguished researchers in science, technology, engineering, mathematics, and medicine, enhancing the state's research capabilities and economic development.

This grant provides financial support for researchers and educators focused on studying and teaching about mushroom-forming fungi in the Pacific Northwest.

The FY24 PCRP Data Science Award mechanism supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data. If successful, the studies will enable progress toward addressing one or more of the FY24 PCRP Overarching Challenges. It is expected that any resources, tools, or computational processes generated by this award will be openly shared with the prostate cancer research and patient community. This mechanism is intended to fund research built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer: Computational biology Bioinformatics Artificial intelligence and machine learning Epidemiology Analysis of omics data Medical imaging Digital pathology Analysis of other clinically annotated datasetsApplications may combine diverse data types for integrative analysis to increase knowledge about prostate cancer with respect to the FY24 PCRP Overarching Challenges. Applications that propose to develop resources or tools that allow research, clinical care, and patient community access to standardized and harmonized datasets for real-time clinical care applications are of particular interest; however, this award must not be used to support the development of new datasets. Studies utilizing data derived from large patient studies that include long-term health records or repositories with well-annotated and high-quality biospecimens are encouraged.Key Features: Research Approach: Applications may propose development of a new data-science-driven tool or apply an existing tool or method to gather and analyze information from large datasets with the intent of advancing prostate cancer research and patient care relative to the FY24 PCRP Overarching Challenges. Inclusion of preliminary data to support the scientific rationale and feasibility of research approaches is strongly encouraged, but not required. Any preliminary data provided should be from the laboratory of the Principal Investigator(s) (PI[s]) or member(s) of the collaborating team. Applicants are encouraged to include plans for rigorous validation, benchmarking, comparisons, and/or evaluations to assess the quality or utility of the tools and/or approaches that will be used or developed under this award. Any datasets used in the study design must be from established, retrospective databases and be sufficient in size to provide appropriate analytical and statistical power. Prospective recruitment of human subjects and/or clinical trials is not allowed under this funding opportunity. Applicants are expected to provide documentation demonstrating access to the appropriate datasets and/or patient samples in numbers sufficient to achieve robust results. Impact: Applications are required to clearly communicate how the proposed quantitative and/or analytical approaches, processes, and/or systems will address and provide a solution to one or more of the FY24 PCRP Overarching Challenges. The potential impact of the research, both short- and long-term, should be clearly described, including how the anticipated outcomes or products are distinct from existing research efforts in this area and/or how they will significantly outperform current approaches in this area. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. Data and Resource Sharing Plan: It is expected that any resources, tools, and computational processes that are developed under this award will be openly shared with the prostate cancer research and patient community. Plans must be provided for how additional data generated by future studies will be incorporated to further inform and refine the data science tools, processes, and/or methods generated and/or used in this study. Refer to the CDMRPs Policy on Data Resource Sharing located on the Electronic Biomedical Research Application Portal (eBRAP) Funding Opportunities Forms web page https://ebrap.org/eBRAP/public/Program.htm for more information about the CDMRPs expectations for making data and research resources publicly available.Partnering PI Option: The FY24 PCRP Data Science Award encourages applications that include meaningful and productive collaborations between investigators. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application; collaborations between data scientists and clinicians are highly encouraged. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project, including the Project Narrative, Statement of Work (SOW) and other required components. If recommended for funding, each PI will be named on separate awards to the recipient organization. Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/ nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Data Science Award should not exceed $1.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $11.2M to fund approximately seven Data Science Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The NSF Research: Campus Cyberinfrastructure grant aims to fund improvements and innovations in campus-level cyberinfrastructure to enhance science applications and research projects, particularly those that bridge geographic digital divides and boost competitiveness in STEM fields.

The FY24 PCRP Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research. All applications for the FY24 PCRP Physician Research Award are to be written by the PI, with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: Physicians with clinical duties and/or responsibilities who, at the application submission deadline, are either in the last year of an accredited graduate medical education program as a resident or fellow or within 5 years of having initiated a faculty appointment (including Instructor positions) are eligible to apply. The PI must demonstrate a commitment to a career as a physician-scientist and investigator at the forefront of prostate cancer research and clinical practice; however, the PI is not required to have previous prostate cancer research experience. The award is intended to provide protection of the PIs time for prostate cancer research. Applications are strongly encouraged to demonstrate protection of at least 20% of the PIs time for prostate cancer research, which is not required to be exclusive to this award but can include effort dedicated to other prostate cancer research projects. Mentor(s): This award requires the involvement of at least one designated mentor with an established research program in prostate cancer, as evidenced by recent publications, active funding, and successful mentorship. In addition, the mentor(s) must demonstrate a commitment to advancing the PIs career in prostate cancer research. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. The inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects is permitted under this funding opportunity but is restricted to studies without clinical trials. Correlative studies associated with an existing clinical trial are particularly encouraged, provided they are determined to be no greater than minimal risk by the Institutional Review Board (IRB) of record and the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight. Researcher Development Plan: An individualized researcher development plan is required and should be prepared with appropriate guidance from the mentor(s). The researcher development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer physician-scientist. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution. Impact: The proposed research must address and provide a solution to one or more of the FY24 PCRP Overarching Challenges and ultimately should have the potential to make a significant impact on the programs mission of eliminating death and suffering from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans, and all the patients and caregivers who are experiencing the impact of the disease.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html. While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP PRA Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $4.80M to fund approximately four PCRP Physician Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Community Assistance Program - State Support Services Element (CAP-SSSE) program provides funding to states to provide technical assistance to communities in the National Flood Insurance Program (NFIP) and to evaluate community performance in implementing NFIP floodplain management activities. Designation, duties and responsibilities of State Coordinating Agencies are found in 44 CFR 60.25. These regulations identify the states commitment to the minimum floodplain management criteria and to demonstrate the capability and responsibility to implement the program. In this way, CAP-SSSE helps to; ensure that the flood loss reduction goals of the NFIP are met, build state and community floodplain management expertise and capability, and leverage state knowledge and expertise in working with their communities.Applicants can submit applications for this funding opportunity through FEMA Grants Outcomes (GO). Access the system at https://go.fema.gov/

This funding initiative provides financial support to Texas-based public and private entities for semiconductor manufacturing and design projects that boost local economies and foster innovation in the industry.

The "DoD Peer Reviewed Cancer, Idea Award" is a grant aimed at supporting innovative and high-risk basic cancer research that introduces new concepts or challenges existing paradigms, with the goal of advancing knowledge in cancer research and treatment for the benefit of Service Members, Veterans, and the American public.

The ITP ASH 2024 grant initiative, offered by SANOFI, is designed to identify and fund projects that aim to close significant healthcare gaps related to the treatment and management of Immune Thrombocytopenia (ITP). ITP is a rare blood disorder characterized by a significantly reduced platelet count, leading to a heightened risk of bleeding and serious health complications such as thrombosis and hematologic malignancy. The chronic nature of ITP often results in a diminished quality of life for patients, manifesting in anxiety, fatigue, and depression due to ongoing concerns about bleeding risks and ineffective current therapies. SANOFI is particularly interested in supporting educational and therapeutic strategies that promise to enhance the clinical handling of ITP, focusing on innovative treatment methodologies and educational activities that can lead to improved patient outcomes. Proposals are invited for projects including, but not limited to, live symposiums at medical conferences, enduring materials for broader educational reach, and both accredited and non-accredited Independent Medical Education (IME) activities. A budget cap of $425,000 is set for the grant, with a strong preference for proposals that incorporate evidence-based approaches and demonstrate potential to address knowledge gaps among healthcare providers, thus improving treatment practices.

The FY24 PCRP Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. The key components of this award mechanism are: Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Projects involving multidisciplinary and/or data science approaches are especially encouraged. Impact: Applications are required to address and provide a solution to one or more of the FY24 PCRP Overarching Challenges. The potential impact of the research, both short-term and long-term, in addressing the FY24 PCRP Overarching Challenge(s) should be clearly described. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. Preliminary Data: Due to this awards emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged, but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. Regardless of whether preliminary data are included, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.New Investigator category: The FY24 PCRP Idea Development Award mechanism encourages research ideas from investigators in the early stages of their careers. The New Investigator category of this award mechanism is designed to allow applicant organizations to name PIs who are early in their faculty appointments or in the process of developing independent research careers. Applications submitted to the New Investigator category will be assessed using different review criteria for personnel (refer to Section II.E.1.a., Peer Review) and are required to include a collaborator (or collaborators) who has (have) experience in prostate cancer research, as demonstrated by a record of funding and publications. The application must describe the potential of the collaboration(s) to be successful and how the collaboration(s) will augment the PIs expertise to better address the research question. In addition, applicants are strongly encouraged to provide a letter of collaboration from the collaborator(s) describing the collaborator(s) involvement in the proposed work. All applicants for the New Investigator category must meet specific eligibility criteria described in Section II.C, Eligibility Information.Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. Each proposed study must include a clearly stated plan for interactions among all team members and organizations involved. The plan must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Idea Development Award should not exceed $1.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $53.76M to fund approximately 28 Idea Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

OJP is committed to advancing work that promotes civil rights and equity, increases access to justice, supports crime victims and individuals impacted by the justice system, strengthens community safety, protects the public from crime and evolving threats, and builds trust between law enforcement and the community. With this solicitation, BJA seeks to fund applications to the FY 2024 Paul Coverdell Forensic Science Improvement Grants Program Competitive (Coverdell Competitive Program) to improve forensic science and medical examiner/coroner services, including services provided by laboratories operated by states and units of local government. This program furthers the DOJs mission to uphold the rule of law, to keep our country safe, and to protect civil rights.